Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Inhibrx Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
1.8
0.2
1.3
Research and development
192
204
113
General and administrative
29.4
128
23.3
Operating expenses
221
332
136
Operating income
-219
-331
-135
Interest expense
31.8
13.5
12.2
Other non-operating income
-20.5
2,019
-5.03
Pre-tax income
-240
1,688
-140
Income tax
0
0
0
Net income
-241
1,688
-140
EBITDA
-218
-329
-133
EPS, basic
-20.48
114.01
-9.04
EPS, diluted
-20.48
112.62
-9.04
Shares, basic (weighted)
11.8
14.8
15.5
Shares, diluted (weighted)
11.8
15
15.5
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
278
153
124
Other current assets
0.37
0.38
0.24
Total current assets
295
160
133
Property, plant and equipment
6.42
6.2
3.73
Lease right-of-use assets
2.95
7.34
5.54
Other non-current assets
3.16
6.83
4.38
Total assets
308
181
146
Accounts payable
11
9.25
5.94
Accrued liabilities
43.3
29.9
25.5
Total current liabilities
56.3
40.7
33.8
Long-term debt
207
0
101
Lease liabilities
1.11
6.45
4.13
Total liabilities
264
47.2
138
Total debt
207
0
101
Paid-in capital
657
240
254
Retained earnings
-614
-106
-246
Shareholders' equity
43.5
134
7.99
Total equity
43.5
134
7.99
Total liabilities and equity
308
181
146
Shares outstanding
47.4
14.5
14.6
Cash flow statement
FY2024
FY2024
FY2025
Net income
-241
1,688
-140
Depreciation and amortization
1.19
2.29
2.48
Stock-based compensation
24.8
58.5
11.1
Change in receivables
-0.54
-0.19
0.2
Change in payables
2.11
17.9
-3.3
Cash from operations
-193
-194
-130
Capital expenditures
-4.59
-2.6
-0.03
Cash from investing
-4.59
-2.6
-0.03
Stock issued
2.32
71.7
1.61
Cash from financing
202
71.7
101
Net change in cash
4.06
-125
-28.4
Free cash flow
-198
-197
-130
Interest paid
26.7
11.5
8.9
Income taxes paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $99.61 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-89.6%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
550.0%
Revenue vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-108.3%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-108.0%
EPS vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-94.0%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-19.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
3.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.07x
Current assets / current liabilities.
Quick ratio
4.75x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.75x
(Cash + short-term investments) / current liabilities.
Debt / assets
114.3%
Total debt / total assets.
Liabilities / assets
134.4%
Total liabilities / total assets.
Net debt
$42.9M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$8.42
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$8.42
Cash from operations / diluted weighted shares.
Book value per share
-$3.60
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
FCF yield
-9.0%
Free cash flow / market cap.
Earnings yield
-9.4%
Net income / market cap (the inverse of P/E).
What was Inhibrx Biosciences, Inc.'s revenue in fiscal 2025?
Inhibrx Biosciences, Inc. reported revenue of $1.3M for fiscal 2025, 550% higher than the year before.
Was Inhibrx Biosciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $140.1M.
How much free cash flow did Inhibrx Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $129.8M minus capital expenditures of $31.0K left free cash flow of -$129.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.